<DOC>
	<DOC>NCT00961532</DOC>
	<brief_summary>The investigators intend to show that DDAVP improves platelet activity from baseline to 60 minutes after treatment start.</brief_summary>
	<brief_title>Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>Spontaneous intracerebral hemorrhage as documented by head CT scan Documented regular aspirin use or VerifyNowASA result of ≤ 550 aspirin reaction units (ARU), indicating antiplatelet medication International normalized ratio (INR) of ≥ 1.7 from coagulopathy or warfarin use History of von Willebrand disease Pregnancy Known hypersensitivity to DDAVP or desmopressin Active cardiovascular disease or unstable angina Hyponatremia or history of hyponatremia Current or historical deep venous thrombosis or pulmonary embolism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>intracerebral hemorrhage</keyword>
	<keyword>platelets</keyword>
</DOC>